AIMS: The present study was undertaken to investigate the relationship between glyoxalase 1 (Glo1) enzyme activity and painful diabetic neuropathy (DN) in patients with diabetes mellitus. METHODS: Glo1 activity and biochemical markers were determined in blood samples from 108 patients with type 1 diabetes, 109 patients with type 2 diabetes, and 132 individuals without diabetes as a control. Painful and painless peripheral DN was assessed and multivariate regression analysis was used to determine independent association of Glo1 activity with occurrence of painful DN. RESULTS: In patients with type 1 and type 2 diabetes mellitus and painful DN compared to patients with painless DN, Glo1 activity was significantly reduced by 12 and 14%, respectively. The increase in Glo1 activity was significantly associated with reduced occurrence of painful DN after adjusting for confounders by multivariate analysis. CONCLUSIONS: Our results demonstrate for the first time that Glo1 activity is lower in patients with both types of diabetes mellitus who were diagnosed with painful DN. These data support the hypothesis that Glo1 activity modulates the phenotype of DN and warrant further investigation into the role of Glo1 in DN.
AIMS: The present study was undertaken to investigate the relationship between glyoxalase 1 (Glo1) enzyme activity and painful diabetic neuropathy (DN) in patients with diabetes mellitus. METHODS:Glo1 activity and biochemical markers were determined in blood samples from 108 patients with type 1 diabetes, 109 patients with type 2 diabetes, and 132 individuals without diabetes as a control. Painful and painless peripheral DN was assessed and multivariate regression analysis was used to determine independent association of Glo1 activity with occurrence of painful DN. RESULTS: In patients with type 1 and type 2 diabetes mellitus and painful DN compared to patients with painless DN, Glo1 activity was significantly reduced by 12 and 14%, respectively. The increase in Glo1 activity was significantly associated with reduced occurrence of painful DN after adjusting for confounders by multivariate analysis. CONCLUSIONS: Our results demonstrate for the first time that Glo1 activity is lower in patients with both types of diabetes mellitus who were diagnosed with painful DN. These data support the hypothesis that Glo1 activity modulates the phenotype of DN and warrant further investigation into the role of Glo1 in DN.
Authors: Ryan B Griggs; Diogo F Santos; Don E Laird; Suzanne Doolen; Renee R Donahue; Caitlin R Wessel; Weisi Fu; Ghanshyam P Sinha; Pingyuan Wang; Jia Zhou; Sebastian Brings; Thomas Fleming; Peter P Nawroth; Keiichiro Susuki; Bradley K Taylor Journal: Neurobiol Dis Date: 2019-02-23 Impact factor: 5.996
Authors: Jacob T Mey; Brian K Blackburn; Edwin R Miranda; Alec B Chaves; Joan Briller; Marcelo G Bonini; Jacob M Haus Journal: Am J Physiol Regul Integr Comp Physiol Date: 2017-10-18 Impact factor: 3.619
Authors: Elisabeth Lodd; Lucas M Wiggenhauser; Jakob Morgenstern; Thomas H Fleming; Gernot Poschet; Michael Büttner; Christoph T Tabler; David P Wohlfart; Peter P Nawroth; Jens Kroll Journal: JCI Insight Date: 2019-06-20
Authors: Jakob Morgenstern; Thomas Fleming; Dagmar Schumacher; Volker Eckstein; Marc Freichel; Stephan Herzig; Peter Nawroth Journal: J Biol Chem Date: 2016-12-12 Impact factor: 5.157
Authors: Katherine M J McMurray; Margaret G Distler; Preetpal S Sidhu; James M Cook; Leggy A Arnold; Abraham A Palmer; Leigh D Plant Journal: Biochem Soc Trans Date: 2014-04 Impact factor: 5.407